Sungkyunkwan University and the University of Michigan reported an oral microbiome nanomedicine designed to boost anticancer immunity, using a small molecule produced by gut bacteria to prime the host response. The approach aims to convert microbiome biology into a directly dosed immunotherapy adjunct. The work follows a surge of interest in “living” or microbiome-coupled therapeutics, but this program is positioned as a compact, oral nanomedicine rather than an ingestible cell product. If translation holds, it could offer a strategy to modulate systemic immune activation without conventional systemic biologics delivery. Separately, USC researchers described a genetic system to expose vulnerable, stem-like cancer cell populations that can evade immune attack, reported in Nature Biomedical Engineering. The platform focuses on hard-to-target tumor cell states that may be shaping resistance to immunotherapy in solid tumors. Together, the updates underscore two converging routes into immunotherapy refinement: microbiome-mediated immune programming for earlier immune engagement, and tumor-state “unmasking” to improve recognition of cells that currently slip past immune pressure.